Harmony Biosciences Holdings, Inc. (HRMY)

NASDAQ: HRMY · Real-Time Price · USD
37.97
-0.08 (-0.21%)
At close: Aug 28, 2025, 4:00 PM
37.97
0.00 (0.00%)
After-hours: Aug 28, 2025, 4:20 PM EDT
-0.21%
Market Cap2.18B
Revenue (ttm)772.53M
Net Income (ttm)180.90M
Shares Out 57.53M
EPS (ttm)3.10
PE Ratio12.27
Forward PE11.51
Dividendn/a
Ex-Dividend Daten/a
Volume426,348
Open38.02
Previous Close38.05
Day's Range37.63 - 38.21
52-Week Range26.47 - 41.61
Beta0.84
AnalystsStrong Buy
Price Target55.33 (+45.72%)
Earnings DateOct 28, 2025

About HRMY

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); a... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Aug 19, 2020
Employees 268
Stock Exchange NASDAQ
Ticker Symbol HRMY
Full Company Profile

Financial Performance

In 2024, HRMY's revenue was $714.73 million, an increase of 22.80% compared to the previous year's $582.02 million. Earnings were $145.49 million, an increase of 12.91%.

Financial Statements

Analyst Summary

According to 9 analysts, the average rating for HRMY stock is "Strong Buy." The 12-month stock price target is $55.33, which is an increase of 45.72% from the latest price.

Price Target
$55.33
(45.72% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will present data from its rare epilepsy pipeline at the 36th International Epilepsy ...

2 days ago - Business Wire

Harmony Biosciences to Participate in 2025 Cantor Global Healthcare Conference

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2025 Cantor Global ...

7 days ago - Business Wire

Harmony Biosciences: Reiterating Buy Ahead Of Data Catalyst For Cannabinoid Drug

Harmony Biosciences remains a Buy due to strong Wakix growth, profitability, and undervalued metrics despite recent setbacks. Upcoming catalysts—especially ZYN002 Phase 3 data in Fragile X—could drive...

8 days ago - Seeking Alpha

Harmony Biosciences Holdings, Inc. (HRMY) Q2 2025 Earnings Call Transcript

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Adam Zaeske - Executive VP & Chief Commercial Officer Brennan Doyle - ...

23 days ago - Seeking Alpha

Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced plans to announce topline data from its phase 3 registrational clinical trial of ZYN002 in Fra...

23 days ago - Business Wire

Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report second quarter 2025 financial results on Tuesday, August 5, 2025, before t...

5 weeks ago - Business Wire

Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the virtual H.C. Wainwright "HCW@Home" ser...

6 weeks ago - Business Wire

Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the presentation of preclinical pharmacological effect data for BP1.15205, an investigational,...

2 months ago - Business Wire

Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced a settlement agreement with Lupin Limited, resolving the patent infringement litigation relat...

3 months ago - Business Wire

Harmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the Goldman Sachs 46th ...

3 months ago - Business Wire

Harmony Biosciences Holdings, Inc. (HRMY) Q1 2025 Earnings Call Transcript

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q1 2025 Earnings Call May 6, 2025 8:30 AM ET Company Participants Brennan Doyle - Head, Investor Relations Jeffrey Dayno - President and Chief Executi...

4 months ago - Seeking Alpha

Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance ​

​PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced strong year-over-year revenue growth for WAKIX® of 20% in the first quarter 2025, on its way ...

4 months ago - Business Wire

Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, before the o...

4 months ago - Business Wire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Shareholders to Connect

NEW YORK, NY / ACCESS Newswire / April 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the C...

5 months ago - Accesswire

Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the presentation of updated data from its Open-Label Extension (OLE) study (ZYN2-CL-017) evalu...

5 months ago - Business Wire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Shareholders to Reach Out

NEW YORK, NY / ACCESS Newswire / April 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the C...

5 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Harmony Biosciences Holdings, Inc. (HRMY) and Encourages Shareholders to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / April 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the C...

5 months ago - Accesswire

Harmony Biosciences Holdings, Inc. (HRMY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / April 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the C...

5 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Harmony Biosciences Holdings, Inc. (HRMY) and Encourages Investors to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the C...

5 months ago - Accesswire

Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the appointment of Ron Philip to the Company's Board of Directors. Ron Philip is the President...

5 months ago - Business Wire

Harmony Biosciences Holdings, Inc. (HRMY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / April 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the C...

5 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Investors to Connect

NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the C...

5 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages Harmony Biosciences Holdings, Inc. (HRMY) Stockholders to Inquire about Securities Investigation

NEW YORK, NY / ACCESS Newswire / March 31, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the ...

5 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Stockholders to Connect

NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the ...

5 months ago - Accesswire

Harmony Biosciences Holdings, Inc. (HRMY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the ...

5 months ago - Accesswire